TD Cowen initiated coverage of Helus Pharma with a rating of Buy and set a new price target of $8.00

Jefferies initiated coverage of Helus Pharma with a rating of Buy and set a new price target of $22.00

6-K - CYBIN INC. (0001833141) (Filer)

6-K - CYBIN INC. (0001833141) (Filer)

D - CYBIN INC. (0001833141) (Filer)

D - CYBIN INC. (0001833141) (Filer)

6-K - CYBIN INC. (0001833141) (Filer)

40-F - CYBIN INC. (0001833141) (Filer)

6-K - CYBIN INC. (0001833141) (Filer)

SUPPL - CYBIN INC. (0001833141) (Filer)

6-K - CYBIN INC. (0001833141) (Filer)

FWP - CYBIN INC. (0001833141) (Subject)

Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM ProgramParticipant rollover is ongoing into the EXTEND long-term study generating long-term safety and durability dataAPPROACH topline data readout on track for Q4 2026 1,2HLP003 previously granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration ("FDA")HLP003 Phase 2 data demonstrated durable efficacy, with a mean ~23-point reduction in Montgomery-Asberg Depression Rating Scale ("MADRS") score from baseline 12 months after two 16 mg doses administered three weeks apart, and 100% response and 71% remission rates based on a MADRS benchmark of ≤10, with remission rising to 100% using more

Issued on behalf of Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP)NEW YORK and TORONTO, July 21, 2026 /CNW/ -- USA News Group - News Commentary - Depression remains one of the most stubborn problems in modern medicine, and the numbers behind it are staggering. Tens of millions of adults live with major depressive disorder, and the majority never reach full remission on the first medication they try. That persistent treatment gap has drawn a wave of biotech and pharmaceutical companies into what is now one of the most closely watched races in interventional psychiatry, each pursuing a different way to reach patients that current antidepressants leave behind.

Major Depressive Disorder Market Poised for Strong Growth as New Drug Innovations Transform Patient CareNEW YORK, July 21, 2026 /CNW/ -- Market News UpdatesNews Commentary - Globally, Major Depressive Disorder (MDD) is a prevalent mental health condition that has seen an improvement in patient outcomes due to new approaches introduced by pharmaceutical companies. Traditionally, treatments focused on boosting serotonin levels or other neurotransmitters, resulting in long waiting periods for patients to notice any changes, without any assurance of effectiveness. However, there is now a shift towards quicker-acting medications, exploration of new biological targets, and the development of perso

Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program Participant rollover is ongoing into the EXTEND long-term study generating long-term safety and durability data APPROACH topline data readout on track for Q4 20261,2 HLP003 previously granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration ("FDA") HLP003 Phase 2 data demonstrated durable efficacy, with a mean ~23-point reduction in Montgomery-Asberg Depression Rating Scale ("MADRS") score from baseline 12 months after two 16 mg doses administered three weeks apart, and 100% response and 71% remission rates based on a MADRS benchmark of ≤10, with remission rising to 100% usi

Issued on behalf of Helus Pharma™Eli Lilly's agreement to acquire AtaiBeckley for up to $3.8 billion hands psychedelic medicine its first large-cap validation, and it lands on a late-stage cohort already carrying pivotal data into the back half of 2026, among them Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP), which has a Phase 3 readout due in the fourth quarterUSA News Group News CommentaryNEW YORK, July 17, 2026 /CNW/ -- For half a century, psychedelic medicine was the field serious money would not touch. That ended this morning. Eli Lilly and Company (NYSE:LLY) agreed to acquire AtaiBeckley Inc. (NASDAQ:ATAI) for $6.75 per share in cash, roughly $2.8 billion, plus up to $2.50 per share in

NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The way Major Depressive Disorder (MDD) is treated is changing faster than it has in years. For decades, most patients relied on traditional antidepressants that often took several weeks to start working—and didn't always help everyone. Today, drug developers are introducing a new wave of treatments designed to work faster, target different areas of the brain, and offer hope to people with treatment-resistant depression. Researchers are also exploring innovative approaches, including NMDA receptor therapies, orexin-targeting drugs, and other next-generation medicines that could significantly improve patient o

- Recently closed $50 million underwritten offering reinforces strong institutional investor conviction and bolsters balance sheet for execution of second Phase 3 HLP003 trial1,2,3, EMBRACE, for potential U.S. FDA New Drug Application in 20281,2,3 - - Phase 3 APPROACH pivotal study of HLP003 in Major Depressive Disorder ("MDD") has surpassed 88% enrollment and is on track for topline data readout in Q4 20262,3 - - HLP003 Phase 2 data demonstrated durability at 12 months following two 16mg doses, with 100% response and 71% remission based on a MADRS benchmark of ≤10, with remission rising to 100% based on recent peer benchmarks of ≤124,5 - - Reported topline results in Phase 2 signal detec

Issued on behalf of Helus Pharma™Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., says its APPROACH Phase 3 trial of HLP003 for adjunctive treatment of major depressive disorder has surpassed 86% enrollment, keeping the FDA Breakthrough-designated program on track for a topline data readout in Q4 2026.NEW YORK and TORONTO, June 26, 2026 /CNW/ -- USA News Group News Commentary, In drug development, enrollment is the quiet variable that decides whether a promising therapy ever reaches a data readout on schedule. Late-stage psychiatric trials are notoriously hard to fill, which is why a clean enrollment update is meaningful. On June 24, 2026, Helus Pharm

NEW YORK and TORONTO, June 25, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), is pleased to announce that it has closed its previously announced underwritten offering of 10,309,280 common shares in the capital of the Company (the "Common Shares") at an offering price of US$4.85 per Common Share for aggregate gross proceeds of US$50 million (the "Offering"). Cantor and Barclays acted as joint bookrunning managers for the Offering. Bloom Burton Securities Inc. and Lucid Capital Markets acted as lead managers for

NEW YORK and TORONTO, June 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), is pleased to announce the pricing of an underwritten offering of 10,309,280 common shares in the capital of the Company (the "Common Shares") at an offering price of US$4.85 per Common Share, for aggregate gross proceeds of US$50 million (the "Offering"). Cantor and Barclays are acting as joint bookrunning managers for the Offering. Bloom Burton Securities Inc. and Lucid Capital Markets are acting as lead managers for the Offering.

Dr. Kramer's 25 years' of experience in neuroscience and proven track record leading global medical launch neuropsychiatry teams will strengthen scientific and clinical engagement NEW YORK and TORONTO, April 16, 2026 (GLOBE NEWSWIRE) -- Helus PharmaTM (NASDAQ:HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), today announced the appointment of Dr. Ken Kramer, PhD as Senior Vice President, Medical Affairs, effective immediately. Dr. Kramer joins Helus with more than two decades of experience leading medical affairs strategy across neuroscience programs, including global launch readiness, eviden

Proven human resources and organizational strategist brings more than two decades of leadership across the pharmaceutical industryAppointment supports Helus Pharma's continued maturation as the company advances its novel clinical pipeline NEW YORK and TORONTO, March 12, 2026 (GLOBE NEWSWIRE) -- Helus PharmaTM (NASDAQ:HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), today announced the appointment of Jill Conwell as Chief People Officer, effective immediately. Conwell brings more than two decades of leadership experience in the life sciences industry, with expertise spanning organizational st

In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus' novel serotonergic agonist ("NSA") portfolio This news release constitutes a "designated news release" for the purpose of the Company's prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. NEW YORK and TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company developing NSAs for serious mental health conditions, today announced the appointment of Dr. Freda Lewis-Hall, DFAPA, MFPM, to its Board of Di

- Cash position of US$195 million as of December 31, 2025, before adjustment for post quarter events -- Topline data readout from the Phase 2 study evaluating HLP004 in generalized anxiety disorder ("GAD") expected in Q1 2026 - This news release constitutes a "designated news release" for the purpose of the Company's prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. BOSTON and TORONTO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- HELUS PharmaTM (NASDAQ:HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), today re

Former President of Shire PLC's ("Shire") Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including senior leadership roles at Astra-Merck and AstraZeneca PLCProven leader in late-stage clinical development, global commercialization, and capital formation across central nervous system ("CNS") programsAppointed as Helus Pharma advances its pipeline toward key clinical milestones, including expected Phase 2 data for HLP004 this quarter and Phase 3 topline data for HLP003 later this year This news release constitutes a "designated news release" for the purpose of the Company's prospectus supplement dated